Molecular mechanisms of tumour necrosis factor signalling via TNF receptor 1 and TNF receptor 2 in the tumour microenvironment

IF 6.6 2区医学 Q1 IMMUNOLOGY

Current Opinion in Immunology Pub Date : 2023-12-27 DOI:10.1016/j.coi.2023.102409

Louisa F Alim , Colm Keane , Fernando Souza-Fonseca-Guimaraes

{"title":"Molecular mechanisms of tumour necrosis factor signalling via TNF receptor 1 and TNF receptor 2 in the tumour microenvironment","authors":"Louisa F Alim , Colm Keane , Fernando Souza-Fonseca-Guimaraes","doi":"10.1016/j.coi.2023.102409","DOIUrl":null,"url":null,"abstract":"<div><p>Tumour necrosis factor (TNF) is a primary mediator of inflammatory processes by facilitating cell death, immune cell activation and triggering of inflammation. In the cancer context, research has revealed TNF as a multifaceted cytokine that can be both pro- or anti-tumorigenic depending on what context is observed. We explore the plethora of ways that TNF and its receptors manipulate the functional and phenotypic characteristics in the tumour microenvironment (TME) on both tumour cells and immune cells, promoting either tumour elimination or progression. Here, we discuss the latest cutting-edge TNF-focused biologics currently in clinical translation that modifies the TME to derive greater immune responses and therapeutic outcomes, and further give perspectives on the future of targeting TNF in the context of cancer by emerging technological approaches.</p></div>","PeriodicalId":11361,"journal":{"name":"Current Opinion in Immunology","volume":"86 ","pages":"Article 102409"},"PeriodicalIF":6.6000,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0952791523001280/pdfft?md5=f3a0c85ff3d1c0b3d585d25a6c7f06f1&pid=1-s2.0-S0952791523001280-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Immunology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0952791523001280","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Tumour necrosis factor (TNF) is a primary mediator of inflammatory processes by facilitating cell death, immune cell activation and triggering of inflammation. In the cancer context, research has revealed TNF as a multifaceted cytokine that can be both pro- or anti-tumorigenic depending on what context is observed. We explore the plethora of ways that TNF and its receptors manipulate the functional and phenotypic characteristics in the tumour microenvironment (TME) on both tumour cells and immune cells, promoting either tumour elimination or progression. Here, we discuss the latest cutting-edge TNF-focused biologics currently in clinical translation that modifies the TME to derive greater immune responses and therapeutic outcomes, and further give perspectives on the future of targeting TNF in the context of cancer by emerging technological approaches.

查看原文本刊更多论文

肿瘤微环境中肿瘤坏死因子通过 TNF 受体 1 和 TNF 受体 2 发出信号的分子机制。

肿瘤坏死因子（TNF）通过促进细胞死亡、激活免疫细胞和引发炎症，是炎症过程的主要介质。在癌症方面，研究发现 TNF 是一种多方面的细胞因子，根据观察到的情况，它既可以促癌，也可以抗癌。我们探讨了 TNF 及其受体操纵肿瘤微环境（TME）中肿瘤细胞和免疫细胞的功能和表型特征，促进肿瘤消退或进展的多种方式。在此，我们将讨论目前正在进行临床转化的以 TNF 为重点的最新前沿生物制剂，这些生物制剂可改变肿瘤微环境以获得更强的免疫反应和治疗效果，并进一步展望在癌症背景下通过新兴技术方法靶向 TNF 的未来。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Opinion in Immunology 医学-免疫学

CiteScore

13.30

自引率

1.40%

发文量

审稿时长

67 days

期刊介绍： Current Opinion in Immunology aims to stimulate scientifically grounded, interdisciplinary, multi-scale debate and exchange of ideas. It contains polished, concise and timely reviews and opinions, with particular emphasis on those articles published in the past two years. In addition to describing recent trends, the authors are encouraged to give their subjective opinion of the topics discussed. In Current Opinion in Immunology we help the reader by providing in a systematic manner: 1. The views of experts on current advances in their field in a clear and readable form. 2. Evaluations of the most interesting papers, annotated by experts, from the great wealth of original publications. Current Opinion in Immunology will serve as an invaluable source of information for researchers, lecturers, teachers, professionals, policy makers and students. Current Opinion in Immunology builds on Elsevier''s reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health. It is a companion to the new Gold Open Access journal Current Research in Immunology and is part of the Current Opinion and Research(CO+RE) suite of journals. All CO+RE journals leverage the Current Opinion legacy-of editorial excellence, high-impact, and global reach-to ensure they are a widely read resource that is integral to scientists'' workflow.